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Abstract
Background: Numerous drugs used in the treatment of psychiatric disorders are substrates of cytochrome P450
enzymes and are potential candidates for drug-drug interactions (DDIs).
Methods: Claims data of a German statutory health insurance company from severely mentally ill patients who
registered in an integrated care contract from August 2004 to December 2009 were analysed. We measured time
periods of concomitant prescription of drugs that have been reported to interact via cytochrome P450, with a focus
on drugs acting as strong inhibitors. Such drug-drug exposure (DDE) is an incontrovertible precursor of DDIs. We
assessed whether potential DDIs were considered clinically relevant based on the prescribing information of the
respective drugs.
Results: Among all 1221 patients, 186 patients (15.2 %; Clopper-Pearson 95 % confidence interval (CI): 13.3–17.4 %)
had at least one DDE prescription, and 58 patients (4.8 %; 95 % CI 3.6–6.1) had at least one DDE prescription
involving a strong cytochrome P450 inhibitor. In 59 patients, (4.8 %; 95 % CI: 3.7–6.2 %) five or more DDEs were
identified, and five or more DDEs with a strong inhibitor were identified in 18 patients (1.5 %; 95 % CI: 0.9–2.3). The
rates of DDEs were 0.27 (Garwood 95%CI: 0.25–0.28) per person-year and 0.07 (95 % CI: 0.07–0.08) for strong-
inhibitor DDEs. Four of the ten most frequent DDEs were identified as clinically relevant, and seven of the eight
most frequent DDEs involving a strong inhibitor were clinically relevant.
Conclusions: The number of patients with DDEs was not alarmingly high in our sample. Nevertheless, prescription
information showed that some prescribed drug combinations could result in serious adverse consequences that are
known to weaken or strengthen the effect of the drugs and should therefore be avoided.
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Background
Pharmacokinetic drug-drug interactions (DDIs) indicate
the influence that one drug has on the blood concentra-
tion of another drug [1–3]. The risk of DDIs is increased
in psychiatric patients [4], as they are often prescribed
several concurrent long-term medications [5–8]. In
many cases, several physicians treat these patients,
which presents a challenge in the medical care of this
patient population because the German health system is
divided into outpatient (primary and secondary care)
and inpatient care. Therefore, mental health specialists
may not perceive somatic co-morbidities in psychiatric
patients. Thus, monitoring of DDIs in this specific popu-
lation is particularly relevant.
In this study we focussed on potential DDIs involving
cytochrome P450 (CYP450) enzymes, as CYP450 en-
zymes metabolise many drugs. Hence, DDIs are likely to
occur [9–12]. Six CYP450 enzymes are involved in the
metabolism of approximately half of all drugs, which
emphasises the importance of CYP450s in the analysis
of DDIs [13]. CYP450 genes [2, 12–15] are subdivided
into different families and subtypes according to their
shared amino acid identity [16]. Drugs can act as sub-
strates, inhibitors, or inducers of CYP450 enzymes [2].
Drugs that act as inhibitors may reduce or disable
enzymatic activity, whereas inducers increase enzymatic
activity [17]. Therefore, we examined the reciprocal
CYP450 interactions of inhibitors and substrates and in-
ducers and substrates. Inhibitors are classified as ‘low’,
‘moderate’, ‘strong’ or ‘without specification’ based on
whether their plasma AUC values increase or clearance
decreases [18]. However, the majority of potential DDIs
experienced by patients may not result in clinically rele-
vant interactions [3]. A prerequisite for the occurrence
of DDIs is the time period of concurrent exposure to
potentially interacting prescribed drugs (drug-drug ex-
posures (DDEs)). DDEs influence the patient’s risk of
developing DDIs [19]. It can be assumed that patients
with a psychiatric illness are particularly prone to DDEs
and, hence, DDIs because they are often prescribed
multi-drug regimens [6]. A British survey conducted at a
psychiatric ward indicated that 19 % of the patients were
prescribed a potentially clinically important CYP2D6
combination, and 6 % were prescribed a potentially clin-
ically important CYP3A4 combination [6]. According to
one review, although millions of patients taking antide-
pressants experience DDEs, the prevalence of clinically
significant DDIs is not clear [20]. In this context, health
insurance data can be utilised to investigate the preva-
lence of DDEs because all medications prescribed in the
outpatient sector are documented for reimbursement
purposes. Thus, we investigated whether drug-
prescribing behaviour poses a relevant hazard for DDIs
in psychiatric outpatient care by using health claims data
from mentally ill patients from an integrated care con-
tract. As DDEs are an incontrovertible precursor of
DDIs, we calculated the frequency of concurrent drug
prescriptions and assessed the clinical relevance of the
potential DDIs in association with prescription informa-
tion for the drugs.
Methods
Data source
Clinical and sociodemographic data were prospectively
collected in an observational study evaluating an integra-
tive outpatient treatment model for seriously mentally ill
patients in Berlin, Brandenburg, and Lower Saxony.
Patients entered the study on July 1, 2004, or at the time
of their entry into the integrative outpatient treatment
model, whichever occurred later. All patients were
followed up until the end of their membership in the in-
tegrative outpatient treatment model, death, or the end
of the study period (December 31, 2009), whichever
came first (see Fischer et al. for details regarding the
study design and participants [21]). The study was
approved by the Ethics Committee of the Charité-Universi-
tätsmedizin Berlin (EA1/088/08). All patients analysed were
insured under the same statutory health insurance
(Deutsche Angestelltenkrankenkasse, ‘DAK’) so that claims
data could be used for this study. Permission to use the
claims data was obtained from the statutory health
insurance. Available data included demographics, clinical
information from psychiatric diagnoses, and information
on all reimbursed outpatient prescriptions. Prescription
data included the anatomical-therapeutic chemical (ATC)
code, which is used to classify substances, and the prescrip-
tion date for every prescribed drug.
Definition of a potential interaction
To define possible inhibitors, inducers and substrates of
CYP450 enzymes from the prescription data, David
Flockhart’s clinically relevant drug interaction table for
CYP450 interactions was used, as it is one of the most
commonly employed data sources for identifying drug
interactions via CYP450s and their clinical relevance
(http://medicine.iupui.edu/clinpharm/ddis/clinical-table/)
[18]. All CYP450-relevant drugs in Flockhart’s table are
classified into inhibitors, inducers or substrates of specific
isoenzymes (1A2, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1 or
3A4, 5, 7). Some drugs act as substrates or inhibitors of
CYP450 enzymes, depending on the interactions of the
victim drug. These drugs were classified as both a
substrate and an inhibitor. We searched all prescrip-
tions successively in chronological order to identify
DDEs in the data. Each entry successively served as the
perpetrator drug. We extracted the prescription date,
the CYP450 isoform, and whether the drug acts as a
substrate, inducer or inhibitor of CYP450 enzymes
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from each perpetrator drug. A DDE was defined as the
prescription of an perpetrator drug (e.g., inhibitor) of a
specific CYP450 isoform (e.g., 2D6) between prescrip-
tions of a DDE victim drug (e.g., substrate) of the same
CYP450 isoform if the time-span between the prescrip-
tion of the two drugs did not exceed 4 weeks (Fig. 1 a).
The 4-week timeframe is consistent with other claims
data studies [22, 23] and we are certain that the
probability of both drugs taken concomitantly is rela-
tively high. Therefore, an perpetrator drug must be
bracketed by a victim drug (‘victim drug’–‘perpetrator
drug’–‘victim drug’). One exception to this definition is
same-day prescriptions in which the perpetrator drug
was not bracketed by the victim drug (Fig. 1 b). The
prescription scheme was not defined as a DDE if the
time-span between the prescriptions exceeded 4 weeks
(Fig. 1 c I-II). Our DDE definition that an perpetrator
drug must be prescribed between prescriptions of a
victim drug was important to exclude changes in drugs
(switches), which were defined as changes to a medica-
tion plan for a patient (Fig. 1 d).
Statistical analysis
Demographic and medical data of the study participants
were analysed descriptively. For proportions, Clopper-
Pearson 95 % confidence intervals (CIs) were calculated,
and for rates, Garwood 95 % CIs were calculated
because for high and low proportions in the data, these
assumptions are a better approximation than the Gaussian
assumption [24]. The most commonly prescribed drugs
and the most commonly prescribed drugs that act on
CYP450 enzymes were identified using the therapeutic/
pharmacological subgroups (level 3) of the ATC system.
The number of patients who were prescribed a drug
scheme that met our DDE definition was counted to esti-
mate the number of patients who potentially experienced
at least one DDE within the observation period. The
number of patients who potentially experienced at least
one DDE with a strong inhibitor was counted to account
for potentially more clinically relevant DDEs.
The observation period varied among patients depend-
ing on the individual duration of the integrative outpatient






Fig. 1 Title: Definition of a DDE. Legend: Dotted line represents the victim drug A. Solid line represents perpetrator drug B. Black arrows point to
relevant drugs for DDE definitions. a Definition of a DDE. Drug B is prescribed between prescriptions of drug A within a 28-day time interval.
b Exceptional case of DDE definition: drugs A and B are prescribed on the same day. c I no DDE by definition: drug A is prescribed, within a
28-day interval drug B is prescribed, but the next prescription of drug A exceeds the 28-day interval. c II no DDE by definition: drug A is
prescribed, the prescription of drug B exceeds the 28-day interval, and the next prescription of drug A lies within the 28-day interval. d no DDE:
drug A is prescribed, then the patient is switched to drug B. No prescription of drug A re-occurs
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calculated. The time at risk was calculated as the time-
span between the first and last occurrence dates in the
data for each patient. Dates of drug prescriptions,
physician contacts, hospital admission and rehabilitation
were included in calculations of the total time interval for
each patient. Patients are not at risk for drug prescriptions
during a hospital or rehabilitation stay. Patients get their
drugs directly from the hospital or rehabilitation centre
and due to the lump-sum based reimbursement system in
the German inpatient care sector, these drugs are not in-
cluded in the health claims data. Therefore, time intervals
for hospital or rehabilitation stays were subtracted from
the total time at risk. The mean duration until the occur-
rence of a prescription with a DDE was calculated in all
patients with at least one DDE prescription. The mean
duration until the event was defined as the average time-
span between the first occurrence in the data and the first
DDE prescription scheme.
DDE combinations that were prescribed most often in
our sample were identified in a first step for all potential
interactions and in a second step for all potential inter-
actions with strong inhibitors. DDE combinations were
analysed with respect to the number of patients who
were prescribed this combination, the DDEs per person-
years and their clinical relevance. The prescribing infor-
mation for brand-name versions of the perpetrator drug
and the interaction victim were screened to evaluate
whether it was advised that the drugs should not be
taken together and whether this DDE was mentioned as
potentially leading to a DDI (i.e., “clinically relevant”).
The impacts of sex and age were evaluated by calculat-
ing stratified DDE exposure rates.
All statistical analyses were performed using R version
3.0.1 [25]. Confidence intervals for rates and proportions
were calculated with the ‘exactci’ package [24].
Results
Participants
Data from 1221 patients (846 females) with a mean age of
47.9 years (standard deviation (SD) 16.2) were available
for analysis. Most patients were diagnosed with depression
(n = 338, 28 %), recurrent depression (n = 304, 24 %), or
schizophrenia (n = 163, 13 %). Patients had a mean obser-
vation period of 4.3 years (SD 1.2) (Table 1).
Prescriptions
Patients were prescribed 17.1 drugs on average (95 %
confidence interval (CI): 17.0–17.3) per person-year.
Most patients were prescribed antidepressants, anti-
bacterials and antipsychotics (Table 2). The most
commonly prescribed antidepressants were citalopram
(n = 436, 35.7 %) and mirtazapine (n = 314, 25.7 %).
The most commonly prescribed antibacterials were
amoxicillin (n = 267, 21.9 %) and doxycycline (n = 236,
19.3 %). Lorazepam (n = 287, 23.5 %) and quetiapine
(n = 203, 16.6 %) were the most commonly prescribed
antipsychotics. The most commonly prescribed drugs
that act on CYP450 enzymes included anti-inflammatory/
antirheumatic products, antidepressants and antipsy-
chotics (Table 3). Ibuprofen (n = 503, 41.2 %) and
diclofenac (n = 450, 36.9 %) were the most commonly
prescribed anti-inflammatory/antirheumatic drugs. The
most frequently prescribed antidepressants were venlafax-
ine (n = 227, 18.6 %) and doxepin (n = 183, 15.0 %). Risper-
idone (n = 164, 13.4 %) and olanzapine (n = 154, 12.6 %)
were the most commonly prescribed antipsychotics.
Number of DDEs
A total of 1122 patients (91.9 %) in our sample were pre-
scribed drugs that may act on CYP450 enzymes. During
the entire 5-year observation period, 186 patients
(15.2 %; 95 %–CI: 13.3–17.4) exhibited at least one DDE
prescription scheme as described above. At least three
DDE prescription schemes were identified in 91 patients
(7.5 %; 95 %–CI: 6.0–9.1), and at least five DDE pre-
scription schemes were identified in 59 patients (4.8 %;
95 %–CI: 3.6–6.1). Prescription of at least one DDE with
a strong inhibitor was observed in 58 patients (4.8 %; 95
%–CI: 3.6–6.1). At least three DDE prescription schemes
with a strong inhibitor were identified in 27 patients
(2.2 %; 95 %–CI: 1.5–3.2), and at least five DDE pre-
scription schemes with a strong inhibitor were
discovered in 18 patients (1.5 %; 95 %–CI: 0.9–2.3).
Person-time analyses
A total of 1393 DDEs were identified in all 1221
patients. The total observation time for all patients was
5221.3 years. We subtracted 8.4 years of hospital time
during which patients were not at risk of being pre-
scribed potentially interacting drugs in the outpatient
sector. Consequently, the total person-time at risk was
5212.8 years. Therefore, the number of prescriptions of
Table 1 Baseline characteristics of all patients (n = 1221)
All patients (n = 1221)
Female, n (%) 846 (69.3)
Age, mean (SD) 47.9 (16.2)
Younger than 35 years, n (%) 269 (22.0)
35–55 years old, n (%) 592 (48.5)
Older than 55 years, n (%) 360 (29.5)
Most common psychiatric diagnosis, n (%)
F32 – Major depressive disorder 338 (27.7)
F33 – Major depressive disorder, recurrent 304 (24.9)
F20 – Schizophrenia 163 (13.4)
F41 – Anxiety disorders 96 (7.9)
F31 – Bipolar disorder 66 (5.4)
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DDEs was 0.27 (95 %–CI: 0.25–0.28) per person-year.
Males had a higher number of prescriptions of DDEs per
person-year than females (males: 0.32, 95 %–CI: 0.30–0.35;
females: 0.24, 95 %–CI: 0.23–0.26). Patients aged 40–65
years had the highest number of DDE prescriptions among
the three age categories (0.34, 95 %–CI: 0.32–0.36). Patients
younger than 40 years or older than 65 years had similar
numbers of DDE prescriptions (younger: 0.18, 95 %–CI:
0.16–0.20; older: 0.18, 95 %–CI: 0.16–0.22). Males aged
40–65 years had a higher number of prescriptions of DDEs
per person-year (0.46, 95 %–CI: 0.41–0.51) than younger
(<40 years; 0.14, 95 %–CI: 0.12–0.18) or older (>65 years;
0.29, 95 %–CI: 0.22–0.37) males. Females aged 40–65 years
had a higher number of prescriptions of DDEs per person-
year (0.29, 95 %–CI: 0.27–0.31) than younger (<40 years;
0.20, 95 %–CI: 0.17–0.23) or older (>65 years; 0.15, 95 %–
CI: 0.13–0.19) females.
The total years to event (prescription of potentially
interacting drugs) were 402.1 years in all 186 patients
who experienced a DDE. Therefore, the duration until
the event was 2.16 years on average (SD 1.41).
Most commonly recorded potential interactions
The most common pairs of prescribed drugs identified
as DDEs were diazepam and omeprazole, doxepin and
venlafaxine, and doxepin and paroxetine (Table 4). Four
of the ten most frequent DDEs were evaluated as clinic-
ally relevant according to the prescribing information.
The most commonly prescribed drug combinations with
a strong inhibitor were amitriptyline and paroxetine and
Table 2 Most frequently prescribed drugs by ATC codes
All patients (n = 1221)
Most commonly prescribed drugs by ATC codes Single prescriptions Number of patients (%)
N06 – Antidepressants 14,001 973 (79.7)
J01 – Antibacterials 3812 885 (72.5)
N05 – Antipsychotics 20,021 844 (69.1)
M01 – Anti-inflammatory/antirheumatic 3728 740 (60.6)
N02 – Analgesics 5996 553 (45.3)
A02 – Drugs for acid-related disorders 3333 475 (38.9)
A03 – Drugs for functional gastrointestinal disorders 1222 366 (30.0)
D07 – Corticosteroids 902 324 (26.5)
R06 – Antihistamines 1573 317 (26.0)
C07 – Beta-blocking agents 2867 307 (25.1)
…
Sum 89,361 N/A
The relative frequency (n) and number of patients who were prescribed the drug (n, %) are shown. Note that patients could be prescribed several drug classes
Table 3 Most frequently prescribed drugs that interact with CYP450 enzymes by ATC codes
All patients (n = 1221)
Prescribed drugs by ATC codes Frequency Number of patients (%)
M01 – Anti-inflammatory/antirheumatic products 3313 713 (58.40)
N06 – Antidepressants 6249 635 (52.0)
N05 – Antipsychotics 5879 471 (38.58)
A02 – Drugs for acid-related disorders 3050 448 (36.69)
N02 – Analgesics 1473 250 (20.48)
J01 – Antibacterials for systemic use 247 146 (11.96)
C10 – Lipid-modifying agents 941 137 (11.22)
C08 – Calcium channel blockers 1195 131 (10.73)
R05 – Cough and cold preparations 165 100 (8.19)
N03 – Antiepileptics 523 80 (6.55)
…
Sum 25,211 N/A
The relative frequency (n) and number of patients who were prescribed the drug (n, %) are shown. Note that patients could be prescribed several drug classes
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Table 4 Most frequent potential drug-drug exposures. The classification of a drug-drug exposure was determined by the prescription
information for the brand-name drugs
Potential drug-drug exposure Frequency Events per 100 person-years
(Poisson exact 95 %–CI)
Number of patients with at
least one DDE (%)
Clinical relevance of a potential interaction (as per prescribing information)
diazepam & omeprazole 52 1.00 (0.74–1.31) 17 (1.39) Omeprazole may increase systemic exposure to diazepam [31]
doxepin & venlafaxine 54 1.03 (0.78–1.35) 15 (1.23) not mentioned
doxepin & paroxetine 44 0.84 (0.61–1.13) 13 (1.06) not mentioned
amitriptyline & omeprazole 58 1.11 (0.84–1.44) 12 (0.98) not mentioned
doxepin & tramadol 51 0.98 (0.73–1.28) 11 (0.90) Tramadol may increase the potential of seizures related to tricyclic
antidepressants. Serotonin syndrome may occur [32] [unclear if due
to CYP interactions]
amitriptyline & paroxetine 29 0.56 (0.37–0.80) 9 (0.74) Patients taking SSRIs should only be treated with amitriptyline with
particular caution [33] [reason not given]
amitriptyline & esomeprazole 31 0.59 (0.40–0.84) 8 (0.66) not mentioned
doxepin & risperidone 95 1.82 (1.47–2.22) 8 (0.66) Mutual reinforcement of the central depressant effect [34]
fluoxetine & omeprazole 11 0.21 (0.11–0.38) 8 (0.66) not mentioned
doxepin & duloxetine 22 0.42 (0.26–0.64) 7 (0.57) not mentioned
…
















Table 5 Most frequent drug-drug exposures with a strong inhibitor in all patients (n = 1221). Classification of the potential drug-drug exposure was determined by the content
of the prescribing information associated with the brand-name drug
Potential drug-drug exposure
(bold = strong inhibitor)
Frequency Events per 100
person-years (95%CI)
Number of patients with at
least one DDE (%)
Clinical relevance of a potential interaction (as per prescribing information)
amitriptyline & paroxetine 29 0.56 (0.37–0.80) 9 (0.74) Patients taking SSRIs should only be treated with amitriptyline with particular
caution [35] [reason not given]
paroxetine & risperidone 21 0.40 (0.25–0.62) 6 (0.49) Paroxetine increases the plasma-concentration of risperidone [36]
codeine & fluoxetine 8 0.15 (0.07–0.30) 5 (0.41) not mentioned [37, 38]
amitriptyline & fluoxetine 16 0.31 (0.18–0.50) 5 (0.41) Taking fluoxetine and amitriptyline in parallel might result in an increased
plasma-concentration of amitriptyline Dose-reduction might be necessary [33]
fluoxetine & tramadol 42 0.81 (0.58–1.09) 5 (0.41) Taking tramadol and fluoxetine in parallel can induce serotonin syndrome [32]
amlodipine & clarithromycin 5 0.10 (0.03–0.22) 4 (0.33) Taking clarithromycin and amlodipine parallel might result in an increased
plasma concentration of amlodipine [39]
clomipramine & paroxetine 76 1.46 (1.15–1.82) 4 (0.33) Paroxetine can increase the plasma concentration of clomipramine [40]
paroxetine & tramadol 6 0.12 (0.04–0.25) 4 (0.33) Taking tramadol and SSRIs [i.e., paroxetine] in parallel can induce serotonin
syndrome [32]. Patients taking tramadol and paroxetine must be monitored
closely [35]
…
















paroxetine and risperidone (Table 5). The eight most
frequent DDEs were identified, and seven of these eight
were evaluated as clinically relevant. According to the
prescribing information, concomitant intake of these
drugs should be avoided.
Discussion
Key results
Our analyses revealed that 15 % of patients were
prescribed a combination of drugs imposing a risk of
DDI at least once; in approximately 5 % of patients, this
combination included a strong inhibitor. Several of the
drug combinations that we identified may cause relevant
interactions. The data suggests that in most of our
patient cases the intended effect of the drugs will be
strengthening.
Interpretations
Other studies have indicated that the proportion of
psychiatric patients at risk of potential DDIs via DDE
ranges from approximately 23 % (Guo et al.) [26] to
28 % (Davies et al.) [6]. In our sample, 15.3 % of the
patients were prescribed at least one drug combination
classified as a DDE. The differences in these numbers
may be attributed to the different methodologies used in
these studies. Davies et al. performed a cross-sectional
study in an inpatient psychiatric ward, while Guo et al.
used Medicaid claims data over 4 years and primarily fo-
cused on the antipsychotics haloperidol, perphenazine,
and chlorpromazine. However, these authors did not
include a longitudinal analysis. The proportion of DDEs
per person-year in our analysis was approximately one-
third. Therefore, our assessment of potential DDEs in
mentally ill patients suggests that the prevalence of DDIs
in our sample is not alarmingly high. However, several of
the identified DDEs are known to lead to clinically rele-
vant DDIs that should be avoided. Psychiatric patients
are often treated across care sectors, which may result in
a lack of communication and information transfer. This
lack of communication may lead to changes in medication
plans and inappropriate drug prescriptions that increase
the patients’ risk of DDIs [27]. One Swiss study noted that
patients are often discharged from hospitals with pre-
scribed drug combinations that may lead to DDEs or DDIs
[28]. One survey indicated that adverse effects due to
DDIs are frequently encountered in the outpatient sector
[29]. German GPs do not act as gatekeepers, and patients
can contact their preferred specialists themselves. A GP
prescribing clarithromycin to a patient might not know
that the patient’s long-term medication plan includes
diazepam prescribed by a mental health specialist. This
lack of communication may increase the patient’s risk for
relevant DDIs. Therefore, our analyses of psychiatric
patients are relevant for the estimation of DDEs, despite
the fact that we only covered outpatient care. Notably, we
identified several combinations of DDEs prescribed by the
same mental health specialist, which is in accord with the
findings of Guo et al. [26]. Initially, we would have
assumed that most DDEs arise from drugs of different
classes that are prescribed by several physicians who are
unknown to the other prescribing physicians.
Strengths and limitations
One particular strength of our secondary data analyses is
that we were able to analyse data from many patients
using their complete prescription records for a long ob-
servation period. The comprehensiveness of these data
provides a complete picture of drug prescriptions for
each insured person, which results in a precise picture
of DDEs. The numbers of identified DDEs were not
alarmingly high in our sample, but our analyses only
covered estimations of pharmacokinetic DDEs caused by
drugs that are metabolised by CYP450 enzymes. There-
fore, the number of DDEs and potential DDIs that are
not due to CYP450 enzymes in our sample is likely to be
even higher and more relevant than we estimated.
A major limitation of our analyses is that we do not
have available data to establish the real linkage between
DDEs and DDIs in the patients. This is because the
health claims data only included information about the
medication prescribed and the prescription date. Hence,
the actual intake of the drugs, effects on biological avail-
ability and possible medical outcomes could not be
assessed. Therefore, it is unclear whether the DDEs
identified based on our definition led to actual simultan-
eous intake of the drugs and eventually to DDIs. How-
ever, even with available medical outcome data, it would
be difficult to identify DDIs beyond severe reactions that
require medical treatment, as patients experiencing a
DDI might not consult a physician but instead stop tak-
ing one of the drugs. A further limitation is that the esti-
mation of DDEs might be imprecise because data on
drug use during inpatient stays and on drugs bought
over the counter are missing. Moreover, specific infor-
mation on the dosage form or packaging size of the pre-
scribed drugs was not available. Dosage information
might be important for estimating the clinical relevance
of DDIs more precisely. In future studies, use of the
‘Pharmazentralnummer’ (PZN; central pharmaceutical
number) could allow more accurate calculations of ex-
posure dates to be made based on the packaging size, as
compared with ATC codes. A US study postulated that
patients must be exposed to two drugs in parallel for at
least ten days to identify potential DDIs in pharmacy
claims data [30]. Unfortunately, we were unable to verify
this constraint because the PZN was not included in the
claims data that we received for the study patients. How-
ever, the use of a time constraint of only 4 weeks and
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the fact that many psychiatric patients are constantly on
medications increases our confidence that our analyses
provide indications of potential DDIs. The specific disease
profiles in our sample limit the generalisability of our
results to the general population, and similar analyses in
other high-risk groups (e.g., patients with chronic condi-
tions or the elderly) are needed.
Outlook
DDEs are potentially hazardous to patient health in frag-
mented health care systems because of the lack of infor-
mation sharing among care sectors. Secondary data
analyses seem promising for the identification of DDEs
and potential DDIs across care sectors, which could re-
duce health care utilisation and costs as a result of
(avoidable) drug interactions. However, DDIs are diffi-
cult to identify in claims data unless an adverse event
occurred and was documented. Claims data must be
merged with patient outcome data to validate whether
our definition of DDEs can be used to identify other
DDIs beyond events requiring hospitalisations. Case
managers of health insurance organisations could use
the DDE definition to screen the prescription data of
their insured persons and determine who is at risk of ex-
periencing DDIs. These insured persons (or their physi-
cians) could then be advised of possible drug alternatives
to avoid DDEs. Costs of outpatient care or hospital
admissions due to DDIs could potentially be reduced,
which would be of (financial) interest to health insur-
ance companies. Claims data that include relevant
prescription information could be stored on health in-
surance cards. The health insurance card could also
store long-term use of over-the-counter drugs if the GP
or pharmacy records these drugs. This information
should be linked with existing interaction databases on a
regular basis to recognise potential DDIs. A comprehen-
sive picture of drug use could prevent clinically relevant
DDIs if data protection can be fully ensured.
Conclusion
Our data suggest that the numbers of patients with
clinically relevant DDIs in our sample is not alarmingly
high. Nevertheless, some prescribed drug combinations
are to be avoided as they might lead to serious adverse
consequences. An improved utilisation of claims data
would allow for an examination of DDEs in routine clin-
ical practice and provide an opportunity to potentially
implement warning systems for DDIs in real-life settings
to optimally minimise the number of patients at risk.
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